TBPH FY 2016 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

FY 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$49M+15.5% YoY

Gross Profit

$46M94.1% margin

Operating Income

-$180M-371.0% margin

Net Income

-$191M-391.9% margin

EPS (Diluted)

$-4.26

Cash Flow

Operating Cash Flow

-$99M

Free Cash Flow

-$101M

Stock-Based Comp.

$41M

Balance Sheet

Total Assets

$639M

Total Liabilities

$289M

Stockholders' Equity

$350M

Cash & Equivalents

$345M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$49M	$42M	+15.5%
Gross Profit	$46M	$37M	+22.1%
Operating Income	-$180M	-$182M	+0.8%
Net Income	-$191M	-$182M	-4.6%